Phase 2a trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapy.
- Conditions
- Advanced pancreatic cancer refractory to gemcitabine and fluoropyrimidine chemotherapy
- Registration Number
- JPRN-UMIN000010111
- Lead Sponsor
- ational Cancer Center Hospital East
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 47
Not provided
1)Prior treatment of medicines or supplements extracted from Arctium lappa linne for pancreatic cancer 2)Lactose intolerance 3)Moderate or massive pleural effusion or ascites 4)Symptomatic brain metastasis or a history of brain metastasis 5)Synchronous or asynchronous (within 3 years) other cancer except carcinoma in situ or intramucosal carcinoma. 6)Psychiatric disease 7)Active infection that requires systemic therapy 8)Other serious complications 9)Pregnant females or nursing mothers who can't stop lactation after the recruitment. Patients or partners, who don't attempt to doing contraception during the study period. 10)Patient is judged as inappropriate for study participation by the investigator for any reason.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method